Benitec Biopharma (NASDAQ: BNTC) reported a 100% response rate among nine patients treated with its experimental gene therapy, BB-301, in an ongoing Phase 1b/2a clinical trial. The October 28 results also showed greater improvements on certain measures among patients receiving a higher dose, while benefits in the lower-dose group persisted for at least 12 months.

‍

For a clinical-stage biotech company whose prospects depend heavily on a single experimental treatment, those results strengthen the case for BB-301 as it approaches a potentially pivotal trial in 2027.

‍

If you’re unfamiliar, the drug targets oculopharyngeal muscular dystrophy (OPMD), a rare inherited disease that progressively weakens the muscles responsible for swallowing.

‍

A small market with significant commercial potential

‍

According to Benitec, approximately 15,000 people across North America, Europe, and Israel have OPMD. There are currently no approved therapies that address the underlying cause of the disease.

‍

BB-301 is designed to change that.

‍

The gene therapy is delivered directly into the throat muscles through a one-time procedure. It works by reducing production of the faulty protein responsible for the disease while providing instructions for cells to produce a functioning replacement.

‍

The commercial appeal here comes from the combination of an unmet medical need, a potentially one-time treatment, and limited direct competition. Gene therapies for rare diseases can also command substantial prices. 

‍

The next major catalyst arrives in 2027

‍

Benitec expects to finalize plans for its potentially pivotal clinical study during the first quarter of 2027, with enrollment targeted for midyear. The company has already discussed the proposed trial design with the FDA.

‍

BB-301 also holds FDA Fast Track and Orphan Drug designations. These can provide development and regulatory advantages, including potential market exclusivity following approval.

‍

Source: 
https://www.globenewswire.com/news-release/2026/10/28/3390135/0/en/benitec-biopharma-announces-positive-interim-phase-1b-2a-results-for-high-dose-bb-301-and-continued-durable-improvements-for-low-dose-bb-301.html

‍